Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc. | Dextromethorphan-bupropion (AXS-05) | Smoking cessation | Phase 2/3 | Data Released | Oral | Anti-Addiction |
| Axsome Therapeutics Inc. | AXS-05 (ADVANCE-2) | Alzheimer's disease agitation | Phase 3 | Data Released | Oral | Psychiatric |
| Axsome Therapeutics Inc. | SYMBRAVO (MoSEIC meloxicam-rizatriptan (AXS-07)) - (EMERGE) | Migraine | Phase 3 | Data Released | Oral | Neurology |
| Ayala Pharmaceuticals Inc. | AL101 - (TENACITY) | Triple negative breast cancer | Phase 2 | Intravenous | Oncology | |
| Aytu BioPharma, Inc. | AR101 (enzastaurin) - (PREVEnt) | Vascular Ehlers-Danlos Syndrome (VEDS) | Phase 3 | Oral | Genetic Disorder | |
| Aytu BioPharma, Inc. | AR101 - (Healight) | COVID-19 | Phase 2 | Endotracheal | COVID-19 | |
| Barinthus Biotherapeutics plc American Depositary Shares | VTP-300 (HBV003) | Hepatitis B (HBV) | Phase 2b | Enrollment Conclusion | Intramuscular | Antiviral |
| Barinthus Biotherapeutics plc American Depositary Shares | VTP-300 (HBV003) | Chronic HPV Infection | Phase 2b | Trial Completed | Intramuscular | Antiviral |
